Journal of the Neurological Sciences
Volume 222, Issue 1 , Pages 7-11 , 15 July 2004

Increased ability of peripheral blood lymphocytes to degrade laminin in multiple sclerosis

  • Takeshi Oki

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +81-43-222-7171x5414; fax: +81-43-226-2160.
    • Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan
    • ,
  • Shunji Takahashi

      Affiliations

    • Environmental Biochemistry, Chiba University School of Medicine, Chiba, Japan
    • ,
  • Satoshi Kuwabara

      Affiliations

    • Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan
    • ,
  • Yasumasa Yoshiyama

      Affiliations

    • Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan
    • ,
  • Masahiro Mori

      Affiliations

    • Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan
    • ,
  • Takamichi Hattori

      Affiliations

    • Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan
    • ,
  • Nobuo Suzuki

      Affiliations

    • Environmental Biochemistry, Chiba University School of Medicine, Chiba, Japan

Received 23 April 2003 ,Revised 5 February 2004 ,Accepted 16 March 2004.

References 

  1. Hartung H-P, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, et al.  Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann. Neurol. 1995;38:186–193
  2. Mosser R, Fassbender K, Kuhnen J, Schwartz A, Hennerici M. Circulating l-selectin in multiple sclerosis patients with active, gadolinium-enhancing brain plaques. J. Neuroimmunol. 1996;65:61–65
  3. Giovannoi G, Lai M, Thorpe J, Kidd D, Chamoun V, Thompson AJ, et al.  Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium-enhanced magnetic resonance imaging. Neurology. 1997;48:1557–1565
  4. Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM, et al.  Neutral metalloproteinases produced by human mononuclear phagocytes. Enzymes profile, regulation, and expression during cellular development. J. Clin. Invest. 1990;86:1496–1502
  5. Conca W, Willmroth F. Human T lymphocytes express a member of the matrix metalloproteinase gene family. Arthritis Rheum. 1994;37:951–956
  6. Leppert D, Waubant E, Galardy R, Bunnett N, Hauser S. T cell geratinases mediate basement membrane transmigration in vitro. J. Immunol. 1995;154:4379–4389
  7. Couldwell WT, Tribolet N, Antel JP, Gauthier T, Kuppner MC. Adhesion molecules and malignant gliomas: implications for tumorigenesis. J. Neurosurg. 1992;76:782–791
  8. Wang BS, McLoughlin GA, Richie JP, Mannick JA. Correlation of the production of plasminogen activator with tumor matastasis in B16 mouse melanoma cell lines. Cancer Res. 1980;40:288–292
  9. Sekiya S, Oosaki T, Suzuki N, Takamizawa H. Invasion potential of human choriocarcinoma cell lines and the role of lytic enzymes. Gynecol. Oncol. 1985;22:324–333
  10. Sugita K, Suzuki N, Isogai E, Niimi H. Serum factors responsible for unusual induction of plasminogen activator activity in tuberous sclerosis. J. Neurol. Sci. 1992;108:202–206
  11. Sugita K, Suzuki N, Shimizu N, Takanashi J, Ishii M, Niimi N. Involvement of cytokines in N-methyl-N′-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. Eur. Neurol. 1993;33:358–362
  12. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227–231
  13. Wilson CL, Matrisian LM. Matrilysin. In:  Parks WC,  Mecham RP editor. Matrix metalloproteinases. San Diego: Academic press; 1998;p. 149–184
  14. Vu TH, Werb Z. Gelatinase B: structure, regulation, and function. In:  Parks WC,  Mecham RP editor. Matrix metalloproteinases. San Diego: Academic press; 1998;p. 115–148
  15. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?. Acta Neurol. Scand. 1988;78:318–323
  16. Mohammad K, Romain H. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 1991;325:467–472
  17. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE. Tumor necrosis factor α production as a possible predictor of relapse in patients with multiple sclerosis. Eur. Cytokine Netw. 1992;3:523–531
  18. Rickermann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al.  Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 1994;44:1523–1526
  19. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al.  Tumor necrosis factor-α messenger RNA expression in patients with relapsing–remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 1995;37:82–88
  20. Martino G, Consiglio A, Franciotta DM, Corti A, Filippi M, Vandenbroeck K, et al.  Tumor necrosis factor α and its receptors in relapsing–remitting multiple sclerosis. J. Neurol. Sci. 1997;152:51–61
  21. Khoury SJ, Orav EJ, Guttmann CRG, Kikinis R, Jolesz FA, Weiner HL. Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. Neurology. 1999;53:758–764
  22. van Boxel-Dezaire AHH, Hoff SCJ, van Oosten BW, Verweij CL, Dräger AM, Adèr HJ, et al.  Decreased interleukin (IL)-10 and increased IL-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 1999;45:695–703
  23. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, et al.  Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology. 1999;53:1397–1401
  24. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992;10:153–187
  25. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, et al.  Breakdown of the blood–brain-barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain. 1990;113:1477–1489
  26. Kwon EE, Prineas JW. Blood–brain-barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J. Neuropathol. Exp. Neurol. 1994;53:625–636
  27. Leppert D, Waubant E, Galary R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 1995;154:4379–4389
  28. Uhm JH, Dooley NP, Stuve O, Francis GS, Duquette P, Antel JP, et al.  Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon β-1b therapy. Ann. Neurol. 1999;46:319–324
  29. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowslki JM, et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987;47:3239–3245
  30. Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in patients with MS: a second prospective study in relapsing patients. Ann. Neurol. 1989;25:43–49

PII: S0022-510X(04)00094-2

doi: 10.1016/j.jns.2004.03.026

Journal of the Neurological Sciences
Volume 222, Issue 1 , Pages 7-11 , 15 July 2004

Article Tools

* Image Usage & Resolution